Hemodynamic effects of inducible nitric oxide synthase and nitrotyrosine generation in heart failure - PubMed (original) (raw)
Hemodynamic effects of inducible nitric oxide synthase and nitrotyrosine generation in heart failure
Marc Vanderheyden et al. J Heart Lung Transplant. 2004 Jun.
Abstract
Objectives: The hemodynamic effects of cardiac inducible nitric oxide synthase (iNOS) and of iNOS-mediated peroxynitrite in patients with left ventricular (LV) dysfunction are unclear. The present study investigates the incidence and functional significance of iNOS expression and nitrotyrosine formation in patients with heart failure.
Methods: LV endomyocardial biopsies obtained from 24 patients with heart failure due to idiopathic dilated cardiomyopathy (ejection fraction [EF] <45% and left ventricular end-diastolic volume index [LVEDVI] >102 ml/m2) were analyzed for iNOS and nitrotyrosine. LV contractile performance was assessed by left ventricular ejection fraction (LVEF) and stroke work normalized for end-diastolic pressure (SW/EDP). LV filling pattern was assessed by Doppler E/A wave ratio, deceleration time (DT) of early LV filling and indexed LV end-diastolic volume normalized for EDP as a marker of diastolic distensibility.
Results: iNOS immunostaining correlated significantly with nitrotyrosine formation (r = 0.86, p < 0.001). In the whole study group, patients expressing iNOS (n = 13) showed larger LV end-diastolic (173 +/-16 vs 128 +/- 9 ml/m2, p = 0.031) and end-systolic volume indices (110 +/- 16 vs 61 +/- 9 ml/m2, p = 0.018) and similar LVEDP (18 +/- 2 vs 21 +/- 2 mm Hg, p = 0.227). In patients with advanced heart failure and reduced pre-load reserve (LVEDP > 16 mm Hg, n = 18), iNOS protein and nitrotyrosine formation correlated positively with LVSW/EDP (r = 0.65, p = 0.03 and r = 0.64, p = 0.04, respectively), DT (r = 0.96, p < 0.01 and r = 0.88, p < 0.01, respectively) and inversely with E/A (r = -0.82, p < 0.01 and r = -0.88, p < 0.01, respectively). In addition, nitrotyrosine formation correlated positively with LVEDVI/EDP (r = 0.64, p = 0.02). Advanced iNOS-positive heart failure patients had a higher LVEDVI/EDP compared with iNOS-negative patients (5.30 +/- 0.64 vs 3.13 +/- 0.34 ml/mm Hg x m2, p = 0.02).
Conclusions: In heart failure, iNOS protein expression is associated with nitrotyrosine formation. Although iNOS-positive patients are generally characterized by larger LV volume and depressed function, the preserved NO generation appears to be associated with higher cardiac work due to the preserved Frank-Starling relationship in end-stage heart failure.
Similar articles
- Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy.
Heymes C, Vanderheyden M, Bronzwaer JG, Shah AM, Paulus WJ. Heymes C, et al. Circulation. 1999 Jun 15;99(23):3009-16. doi: 10.1161/01.cir.99.23.3009. Circulation. 1999. PMID: 10368118 - Left ventricular contractile effects of inducible nitric oxide synthase in the human allograft.
Paulus WJ, Kästner S, Pujadas P, Shah AM, Drexler H, Vanderheyden M. Paulus WJ, et al. Circulation. 1997 Nov 18;96(10):3436-42. doi: 10.1161/01.cir.96.10.3436. Circulation. 1997. PMID: 9396439 - Assessment of left ventricular systolic function using echocardiography in patients with preserved ejection fraction and elevated diastolic pressures.
Dokainish H, Sengupta R, Pillai M, Bobek J, Lakkis N. Dokainish H, et al. Am J Cardiol. 2008 Jun 15;101(12):1766-71. doi: 10.1016/j.amjcard.2008.02.070. Epub 2008 Apr 9. Am J Cardiol. 2008. PMID: 18549856 - The role of nitric oxide in the failing heart.
Paulus WJ. Paulus WJ. Heart Fail Rev. 2001 Mar;6(2):105-18. doi: 10.1023/a:1011453809750. Heart Fail Rev. 2001. PMID: 11309529 Review.
Cited by
- Nitric oxide and peroxynitrite in health and disease.
Pacher P, Beckman JS, Liaudet L. Pacher P, et al. Physiol Rev. 2007 Jan;87(1):315-424. doi: 10.1152/physrev.00029.2006. Physiol Rev. 2007. PMID: 17237348 Free PMC article. Review. - Hemodynamic Response to Acute Volume Load and Endomyocardial NO-synthase Gene Expression in Heart Transplant Recipients.
Kobediona M, Bartunek J, Delrue L, Van Durme F, Lau CW, Moya A, Verstreken S, Heggermont W, Dierckx R, Goethals M, Vanderheyden M. Kobediona M, et al. Transplant Direct. 2022 May 26;8(6):e1336. doi: 10.1097/TXD.0000000000001336. eCollection 2022 Jun. Transplant Direct. 2022. PMID: 35651587 Free PMC article. - Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure.
Ng ML, Ang X, Yap KY, Ng JJ, Goh ECH, Khoo BBJ, Richards AM, Drum CL. Ng ML, et al. Biomedicines. 2023 Mar 15;11(3):917. doi: 10.3390/biomedicines11030917. Biomedicines. 2023. PMID: 36979896 Free PMC article. Review. - Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure.
Ungvári Z, Gupte SA, Recchia FA, Bátkai S, Pacher P. Ungvári Z, et al. Curr Vasc Pharmacol. 2005 Jul;3(3):221-9. doi: 10.2174/1570161054368607. Curr Vasc Pharmacol. 2005. PMID: 16026319 Free PMC article. Review. - Oxidative Stress-Related Parthanatos of Circulating Mononuclear Leukocytes in Heart Failure.
Bárány T, Simon A, Szabó G, Benkő R, Mezei Z, Molnár L, Becker D, Merkely B, Zima E, Horváth EM. Bárány T, et al. Oxid Med Cell Longev. 2017;2017:1249614. doi: 10.1155/2017/1249614. Epub 2017 Nov 9. Oxid Med Cell Longev. 2017. PMID: 29250299 Free PMC article.